Open Peer Review on Qeios

ESO-1 (161-180) Peptide Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>ESO-1 (161-180) Peptide Vaccine</u>. NCI Thesaurus. Code C28775.

A recombinant 19-residue peptide vaccine consisting of amino acids 161 through 180 of the cancer/testis (CT) antigen. ESO-1 (161-180) peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI04)